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Take-home message: Any benefit of social distancing on TB deaths is likely to be outweighed b y 
health service disruption. As such, it is crucially important to maintain and strengthen TB-related 
health services during, and after, the COVID-19 pandemic. 
 
  
Before the COVID-19 pandemic, over 4000 people were dying from tuberculosis (TB) every day.[1] As 
with past emergencies[2], the impact of COVID-19 on TB outcomes is a serious cause for concern[3] 
but is currently unknown. Health systems overload, due to high numbers of COVID-19 cases, as well 
as interventions necessary to limit the transmission of SARS-CoV-2, could result in severe reductions 
in health service availability and access for the detection and treatment of TB cases.[4] However, 
physical distancing interventions could also limit Mycobacterium tuberculosis transmission outside of 
households, where most transmission occurs.[5] This has not been adequately explored in existing 
work,[6-8] and it is currently unclear whether social distancing could compensate for disruptions in 
TB services, and what the impact of these combined COVID-19 disruption effects on TB burden is 
likely to be. 
We used a mathematical model of TB with an age-specific contact matrix calibrated to data from 
China, India and South Africa,[9] key high TB burden countries accounting for approximately 40% of 
global TB cases,[1] to estimate the relative impact of reductions in social contacts and health 
services due to COVID-19 on TB burden. We considered three scenarios for reductions in different 
forms of social contact, reweighting contact rates between age groups to reflect large reductions in 
the number of contacts per day occurring in schools (0%, 50%, and 100% in the low, medium, and 
high scenarios respectively), transport (30%, 60%, 80%) and leisure settings (50%, 70%, 80%), and 
smaller reductions in contacts occurring in workplaces (20%, 30%, 50%), which are within the range 
of already observed reductions.[10,11] We assumed that mean numbers of contacts occurring 
within home settings did not change, although we did not model households explicitly. We also 
considered three scenarios for TB health service disruption, which could be a result of a number of 
factors such as decreases in diagnostic activities and clinic visits, delays in diagnosis and treatment 
initiation, and reduced treatment support. These were modelled as reductions in the proportion of 
incident TB cases detected and detected cases successfully treated: a 20%, 50% or 80% relative 
reduction in both simultaneously. Although our scenarios are in line with initial evidence on 
reductions in tested and notified cases [12,13], we examined a wide range of disruptions here as the 
scale of these is, as yet, largely unknown.. Both reductions in social contact and in health service 
parameters were implemented from early 2020, and were assumed to last for six months. We 
estimated the cumulative change in TB incidence and deaths over 5 years for each combination of 
these scenarios compared to a baseline with no change. 
Results suggest that any potential ‘benefit’ of social distancing on TB burden is likely to be larger for 
TB disease incidence, than for TB deaths (Fig1 a-c vs d-f). Such that in some scenarios where health 
services are less affected, lower numbers of TB cases may occur over this period. However, this is 
not considered the most plausible scenario based on current anecdotal information in most low and 
middle income settings. In addition, this potential reduction in the impact on TB burden tends not to 
be true for TB deaths, which show a net increase in deaths in all scenarios with some level of health 
service disruption. In scenarios with substantial health service disruption, we project an increase in 
both TB cases and deaths, regardless of the level of social distancing. 
In our worst case scenario, where COVID-19 interventions to reduce social contacts are minimal, but 
TB health services are badly affected, results suggest an increase in TB deaths of 23,516 (range 
18,560-27,940), 149,448 (85,000-233,602) and 28,631 (19,963-40,011) in China, India and South 
Africa, respectively between 2020-2024, totalling 201,595 (123,523-301,553) additional TB deaths in 
these three countries alone. This would be an increase of 8-14% in cumulative TB deaths for that 
period. However, if these countries are able to minimise the impact on TB health service delivery, 
major reductions in social contacts could keep the number of additional TB deaths comparatively 
low. 
These impacts on TB burden are likely to be felt globally, particularly for TB mortality in the short 
term. However, our results suggest that the setting-specific nature of the TB epidemic and 
differences in changing social contacts and service delivery could create highly he terogeneous 
changes to long-term TB incidence. For example, higher proportions of TB resulting from reactivation 
in China[14] suggest that reductions in social contacts may have less influence on incidence than 
elsewhere. Further important factors for consideration include that health service declines are likely 
to have a greater impact on patients with drug-resistant TB (which we do not consider here). Indeed, 
a more detailed analysis of health service availability than our simplified consideration of case 
detection and treatment success, while not yet possible due to the lack of data, is necessary to 
understand and mitigate for these changes. Our model is also limited in its consideration of each 
country as a whole, when disruptions are likely to be geographically heterogeneous and specific to 
local measures. Meanwhile external factors such as increases in poverty and reductions in access to 
antiretroviral therapy in settings with a high HIV prevalence could also increase rates of progression 
to TB disease. In addition, we estimate the impact of a six month disruption, but given subsequent 
pandemic waves are anticipated,[15] and are likely to require further mitigation measures, estimates 
presented here could be considered conservative. Finally, the as-yet-unknown potential for an 
increase in risk of severe COVID-19 in patients with active or previous TB, as well as an increase in 
risk of exposure to SARS-CoV-2, could have major implications for TB burden.[16,17] 
It is, however, imperative that continued access to TB diagnosis and care is ensured, together with 
the collection and regular reporting of TB indicators, to allow the impact on TB to be both measured 
and mitigated. Research, guidance and funding are urgently required to identify, prioritize and 
deliver those intervention that could best alleviate the impact of COVID-19-related disruptions. 
These will differ by timescale. Interventions necessary to prioritize during disruptions, such as digital 
adherence technologies to support patient treatment remotely, will be different to those to 
prioritize afterwards, such as active case finding activities focused on the household, where social 
contacts and transmission may have been concentrated. It is vital that decision-makers and funders 
recognise the importance of this issue and act to ensure that innovative approaches to people -
centered TB care are rapidly scaled up, so that the fight to end one pandemic does not worsen 
another. 
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Figure 1: Cumulative change in TB (a-c) incidence and (d-f) deaths over 5 years as a result of social 
and/or health system disruption due to the COVID-19 pandemic for (a,d) China, (b,e) India and (c,f) 
South Africa. Results show the median of model runs, while whiskers denote the range of run results. 
Small black crosses indicate author assessment of most plausible scenarios based on current 
anecdotal information. Note y-axes scales differ by country and indicator. 
 
